W. R. Grace & Co. and Formac Pharmaceuticals NV will present positive data from initial human studies enabled by the companies’ unique mesoporous silica-based drug delivery technology at the 2012 AAPS conference. This novel technology is designed to open up new avenue for the development of poorly soluble compounds.
A clinical study demonstrated the bioavailability enhancing properties of silica in humans. Improved bioavailability enables active pharmaceutical ingredients (APIs) to more effectively absorb into the body. In this study, the bioavailability profile of fenofibrate formulated with silica was compared to the marketed micronized formulation (Lipanthyl). The study results show a 54% higher bioavailability for the silica formulation than the marketed formulation.
The study confirmed the numerous promising findings obtained in preclinical models and exemplifies that the Grace and Formac Pharmaceuticals partnership can provide a fully integrated, cost effective and innovative solution, from early phases to commercial production, for the development of poorly soluble compounds.
Grace and Formac partnered in 2011 to optimize and commercialize the silica based technology that Formac created. Grace is leveraging its silica R&D and manufacturing expertise to develop a portfolio of silicas that can give pharmaceutical companies an optimized and tailored drug delivery solution for their drug.
Release Date: April 23, 2012
Source: W.R. Grace & Co.
Formac Pharmaceuticals
Filed Under: Drug Discovery
